Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients

Imagem de Miniatura
Arquivos
art_AFONSO_PhosphomTOR_in_nontumour_and_tumour_bladder_urothelium_Pattern_2014.PDF (636.85 KB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPANDIDOS PUBL LTD
Autores
AFONSO, Julieta
SILVA, Vitor Moreira Da
AMARO, Teresina
SANTOS, Iucio L.
Citação
ONCOLOGY LETTERS, v.8, n.4, p.1447-1454, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Urothelial bladder carcinoma (UBC) is heterogeneous in its pathology and clinical behaviour. Evaluation of prognostic and predictive biomarkers is necessary, in order to produce personalised treatment options. The present study used immunohistochemistry to evaluate UBC sections containing tumour and non-tumour areas from 76 patients, for the detection of p-mTOR, CD31 and D2-40 (blood and lymphatic vessels identification, respectively). Of the non-tumour and tumour sections, 36 and 20% were scored positive for p-mTOR expression, respectively. Immunoexpression was observed in umbrella cells from non-tumour urothelium, in all cell layers from non-muscle-invasive (NMI) tumours (including expression in superficial cells), and in spots of cells from muscle-invasive (MI) tumours. Positive expression decreased from non-tumour to tumour urothelium, and from pTl/pTis to pT3/pT4 tumours; however, the few pT3/pT4 positive cases had worse survival rates, with 5-year disease-free survival being significantly lower. Angiogenesis occurrence was impaired in pT3/pT4 tumours that did not express p-mTOR. In conclusion, p-mTOR expression in non-tumour umbrella cells is likely a reflection of their metabolic plasticity, and extension to the inner layers of the urothelium in NMI tumours is consistent with an enhanced malignant potential. The expression in cell spots in a few MI tumours and absence of expression in the remaining tumours is intriguing and requires further research. Additional studies regarding the up- and downstream effectors of the mTOR pathway should be conducted.
Palavras-chave
p-mTOR, urothelial bladder cancer, pattern of expression, umbrella cells
URI
https://observatorio.fm.usp.br/handle/OPI/12918
Referências
  1. Amin MB, 2005, URINARY BLADDER CANC
  2. Kaufman DS, 2009, LANCET, V374, P239, DOI 10.1016/S0140-6736(09)60491-8
  3. Rosner M, 2008, MUTAT RES-REV MUTAT, V659, P284, DOI 10.1016/j.mrrev.2008.06.001
  4. Ueng SH, 2012, INT J CLIN EXP PATHO, V5, P806
  5. Knowles MA, 2009, CANCER METAST REV, V28, P305, DOI 10.1007/s10555-009-9198-3
  6. Pinto-Leite R, 2012, J TOXICOL ENV HEAL A, V75, P788, DOI 10.1080/15287394.2012.690325
  7. Dormond-Meuwly A, 2011, BIOCHEM BIOPH RES CO, V407, P714, DOI 10.1016/j.bbrc.2011.03.086
  8. Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
  9. Herberger B, 2007, CLIN CANCER RES, V13, P4795, DOI 10.1158/1078-0432.CCR-07-0738
  10. Schultz L, 2010, CANCER-AM CANCER SOC, V116, P5517, DOI 10.1002/cncr.25502
  11. Hansel DE, 2010, AM J PATHOL, V176, P3062, DOI 10.2353/ajpath.2010.090872
  12. Khandelwal P, 2009, AM J PHYSIOL-RENAL, V297, pF1477, DOI 10.1152/ajprenal.00327.2009
  13. Nelson V, 2013, EXPERT OPIN INV DRUG, V22, P715, DOI 10.1517/13543784.2013.787066
  14. Dobashi Y, 2011, INT J CLIN EXP PATHO, V4, P476
  15. Shariat SF, 2006, J UROLOGY, V176, P2414, DOI 10.1016/j.juro.2006.08.004
  16. Seront E, 2012, ANN ONCOL, V23, P2663, DOI 10.1093/annonc/mds057
  17. Sato T, 2010, ONCOGENE, V29, P2746, DOI 10.1038/onc.2010.28
  18. Fasolo A, 2012, CURR PHARM DESIGN, V18, P2766
  19. Leal P, 2013, ARCH PATHOL LAB MED, V137, P552, DOI 10.5858/arpa.2012-0032-OA
  20. Gentzler RD, 2012, EXPERT OPIN THER TAR, V16, P481, DOI 10.1517/14728222.2012.677439
  21. Sun CH, 2011, HISTOPATHOLOGY, V58, P1054, DOI 10.1111/j.1365-2559.2011.03856.x
  22. Zhou HY, 2011, CURR PROTEIN PEPT SC, V12, P30
  23. An JY, 2010, INT J CANCER, V126, P2904, DOI 10.1002/ijc.24872
  24. Afonso J, 2009, HISTOPATHOLOGY, V55, P514, DOI 10.1111/j.1365-2559.2009.03425.x
  25. Yecies JL, 2011, J MOL MED-JMM, V89, P221, DOI 10.1007/s00109-011-0726-6
  26. Colombel M, 2008, EUR UROL SUPPL, V7, P618, DOI 10.1016/j.eursup.2008.08.002
  27. Yecies JL, 2011, CANCER RES, V71, P2815, DOI 10.1158/0008-5472.CAN-10-4158
  28. Apodaca G, 2004, TRAFFIC, V5, P117, DOI 10.1046/j.1600-0854.2003.00156.x
  29. Strimpakos AS, 2009, CANCER TREAT REV, V35, P148, DOI 10.1016/j.ctrv.2008.09.006
  30. Darb-Esfahani S, 2009, J CANCER RES CLIN, V135, P933, DOI 10.1007/s00432-008-0529-5
  31. Reuter VE, 2006, UROLOGY, V67, P11, DOI 10.1016/j.urology.2006.01.037
  32. Fahmy M, 2013, HUM PATHOL, V44, P1766, DOI 10.1016/j.humpath.2012.11.026
  33. Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014
  34. Bellmunt J, 2011, ANN ONCOL S, V22, P45
  35. Bradshaw-Pierce EL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058089
  36. Cejka D, 2008, ANTICANCER RES, V28, P3801
  37. Cheung G, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-13
  38. Eble JN, 2004, PATHOLOGY GENETICS T
  39. Edge SB, 2010, AJCC CANC STAGING MA, P497
  40. Faivre S, 2008, EXPERT OPIN INV DRUG, V17, P1619, DOI [10.1517/13543784.17.11.1619 , 10.1517/13543780802445705]
  41. Faried LS, 2008, MOL CARCINOGEN, V47, P446, DOI 10.1002/mc.20402
  42. Frost P, 2013, J ONCOL, V2013, DOI 10.1155/2013/897025
  43. Gibbons James J, 2009, Semin Oncol, V36 Suppl 3, pS3, DOI 10.1053/j.seminoncol.2009.10.011
  44. Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051
  45. Korkolopoulou P, 2012, BJU INT, V110, pE1237, DOI 10.1111/j.1464-410X.2012.11569.x
  46. Makhlin I, 2011, BJU INT, V108, pE84, DOI 10.1111/j.1464-410X.2010.09844.x
  47. Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352
  48. Mostofi FK, 1999, INT HISTOLOGICAL CLA, P3
  49. Muller J, 2013, INT J CANCER, V132, P1333, DOI 10.1002/ijc.27768
  50. O'Reilly T, 2011, ANTI-CANCER DRUG, V22, P58, DOI 10.1097/CAD.0b013e3283400a20
  51. Park Se Jun, 2011, Korean J Urol, V52, P466, DOI 10.4111/kju.2011.52.7.466
  52. Pinto-Leite R, 2013, BIOMED PHARMACOTHER, V67, P123, DOI 10.1016/j.biopha.2012.11.007
  53. Pinto-Leite R, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-3
  54. Polette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008
  55. Rai JS, 2010, UROL ONCOL-SEMIN ORI, V28, P134, DOI 10.1016/j.urolonc.2009.03.023
  56. Seager CM, 2009, CANCER PREV RES, V2, P1008, DOI 10.1158/1940-6207.CAPR-09-0169
  57. Serrano C, 2012, CANCER TREAT REV, V38, P311, DOI 10.1016/j.ctrv.2011.10.007

Coleções
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - ODS/03